Matthew Perrone, Las Vegas Sun: September 7, 2022 This AP article was published in numerous newspapers and websites A closely watched experimental drug for Lou Gehrig’s disease got an unusual second look from U.S. regulators on Wednesday, following intense pressure to approve the treatment for those with the fatal illness. Patients and their families have […]
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Trump Covid Report Stirs Calls for FDA to Rebuild Public Trust
Celine Castronuovo and Jeannie Baumann, Bloomberg Law, August, 26, 2022 A House report detailing coordinated attempts by Trump White House officials to influence the FDA’s pandemic response underscores the need for more transparency at an agency that’s facing historically low public trust, health policy analysts say. The House Select Subcommittee on the Coronavirus Crisis said this […]
Read More »FDA official bolting to Big Tobacco shines a light on the agency’s revolving-door problem
Grid News, August 3, 2022: An FDA official leaving FDA’s Tobacco Science Office to work for Big Tobacco shines a light on the agency’s revolving-door problem. We explain why this undermines FDA’s authority.
Read More »Science says later school start times are healthier. Some High Desert schools aren’t so sure
Daily Press, August 1, 2022: Science says later school start times are healthier. We explain that “If you were designing something to make it very difficult for high school students to learn and concentrate, starting classes at 8 or earlier is what you would design.” But some students disagree.
Read More »Bipartisan bill on antibiotics faces crucial stretch
The Hill, August 1, 2022: A health care bill is facing criticism from some experts who say it could lead to huge spending on new antibiotic drug development that may not improve patient outcomes in the long run. We point out that it could increase antibiotic resistance rather than solve the problem.
Read More »